A Phase 3 clinical trial of the investigational drug tofersen in patients with MND caused by the faulty SOD1 gene, has shown it can slow and reduce progression of the disease if taken over a period of 12 months. Results of the clinical trial indicated a notable reduction in the rate of decline in patient mobility and lung function after a year of taking the drug. More information here.
